AKRO News and Press, Akero Therapeutics Inc. From 02/06/24

2024-02-06 12:58:10 ET More on Akero Therapeutics, 89bio, etc. Biotech And Pharma Diversification Pays Off Sagimet: Additional Upside Possible After Latest NASH Data Release Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play Karuna’s KarXT ...

2024-02-06 10:00:02 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...

2024-02-06 08:37:26 ET Losers: BioRestorative Therapies ( BRTX ) -56% . announces exercise of warrants and issuance of new warrants in a private placement for $8.1 Million gross . Peraso ( PRSO ) -32% . Solidion Technology ( STI ) -20% . Symboti...

2024-02-06 07:25:47 ET More on Eli Lilly Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Biotech And Pharma Diversification Pays Off Eli Lilly: The Cupboard Is Fully Stocked Eli Lilly beats top-line and bottom-line estimates; ...

2024-01-16 16:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will pr...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2024-01-02 11:12:57 ET Summary Madrigal Pharmaceuticals, Inc. stock has rallied 70% since late October due to a decrease in competitive concerns and a large secondary offering. The company's candidate resmetirom is expected to be the first approved therapy for NASH in March 2024. ...

Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to Review Phase 3 Study and Regulatory Path for Treatment of NASH/MASH Patients with Compe...

2023-12-06 18:59:01 ET Summary 89bio, Inc.'s successful end-of-phase 2 meeting with the FDA gained alignment for Potential Accelerated Approval of pegozafermin; such studies to be advanced are ENLIGHTEN-Cirrhosis and ENLIGHTEN-Fibrosis. Akero will report 96-week data from the SYMM...